The MHRA’s Shift Towards Flexible Licensing for Rare Disease Treatments

In a small, dimly lit clinic on the outskirts of London, a group of families gathers for a support meeting. Each one is grappling with the weight of a rare disease that affects their child—a battle often waged in hospitals where treatments are scarce, and the wait for approval can feel eternal. For them, the news from the Medicines and Healthcare products Regulatory Agency (MHRA) offers a glimmer of hope. The agency is exploring a more flexible, iterative licensing regime specifically for treatments targeted at rare diseases, a move aimed at transforming the lives of the 1 in 2,000 children born with conditions unseen by most.

The Urgent Need for Change

The MHRA’s recent policy paper paints a stark picture: “Current regulatory pathways assume large populations, standard endpoints, and multiple trials.” This system, designed for widespread diseases, fails to accommodate the particular needs of orphan medicines—treatments designated for diseases affecting fewer than five in every 10,000 people. “Rare disease therapies, however, need flexibility, adaptable trial designs, real-world evidence, and expedited review—needs that existing frameworks do not adequately support,” the agency explains.

As it stands, the traditional licensing regime places immense challenges on developers. Catherine Drew, a partner at Pinsent Masons, elaborates: “The conventional routes involve lengthy approval processes that can take years and require data from vast patient populations that simply don’t exist for rare diseases.” With many orphan drugs having only a handful of clinical trials to reference, the requirement for large patient populations can prove impossible.

A Vision for the Future

The MHRA is embarking on a journey to reform. By spring 2026, it plans to publish a draft framework detailing a new licensing approach. Central to this will be the concept of granting “preliminary approvals” based on “appropriate, albeit limited, evidence.” This could mean relying less on exhaustive clinical trials and more on innovative data sources like real-world evidence or natural history comparators. But what does this shift actually look like?

Key Features of the Proposed Framework

• Iterative Licensing: Allowing for continuous reassessment of a drug’s efficacy post-approval.
• Real-World Data Utilization: Employing real-world data collected from patients outside of clinical trials.
• Global Rare Disease Registries: Pooling data internationally to enhance sample sizes and outcomes.

The proposal not only simplifies the pathway for approval but also aligns regulatory processes with health technology assessments, overseen by the National Institute for Health and Care Excellence (NICE). Yet, these changes spark a critical concern: the fate of financial mechanisms that govern access to these therapies once they are approved.

The Price of Innovation

While the MHRA aims to streamline regulations, the worry remains that funding pathways may not keep pace. Gareth Morgan, also from Pinsent Masons, highlights a glaring inconsistency: “With orphan medicines, the market manufacturers are supplying to is often very small. The price they need to charge healthcare providers like the NHS to obtain a fair return on their investment is significantly higher than that of average medicinal products.”

NICE has expressed that there is flexibility within its current framework, allowing for costs that could be up to ten times the average for rare disease therapies. Yet, this potential leeway often fails to translate into practical solutions for developers. Morgan says, “In our experience, many clients struggle to get NICE on board due to high levels of statistical uncertainty around outcomes that low patient numbers bring. This uncertainty bleeds into pricing negotiations, where NICE may infer lower efficacy, applying a lower value to the product than manufacturers can accept.”

The Call for Alignment

If the MHRA’s ambitious plans are to succeed, alignment with NICE and other stakeholders will be crucial. As Morgan succinctly puts it, “It is imperative that the MHRA seeks alignment of pricing issues with a revised regulatory pathway for orphan medicines if manufacturers are truly going to be incentivized.” This is a matter not only of regulatory approval but also of ensuring that patients can access life-saving treatments without being price-gouged.

As the sun sets outside the London clinic, families find solace in one another’s company, sharing stories of hope and resilience. For them, the MHRA’s forthcoming changes symbolize a potential dawn for millions living with rare diseases. With the agency’s innovative approach, the dream of accessibility and affordability for orphan medicines may one day become a reality, shaping both the future of regulatory frameworks and the very lives of those seizing their futures—one treatment at a time.

Source: www.pinsentmasons.com